Delivery Order SPE2DB20D9354-SPE2DB25FX7W5
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $4,169.59 to DMS Pharmaceutical Group Inc. for the supply of Xtandi 80 mg tablets (60-count units). The contract, issued on July 22, 2025, with an ultimate completion date of July 23, 2025, is structured as a firm fixed-price delivery order with no set-aside designation. The awardee, a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will fulfill this order from its location in the same city....
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $8,339.18 by the Defense Logistics Agency on July 21, 2025, for the supply of Xtandi 80 mg tablets (60-count units). The contract, which carries no set-aside designation, is scheduled for completion by July 22, 2025, with performance at the vendor's Park Ridge location. This delivery order is issued under DMS Pharmaceutical...
- The Defense Logistics Agency awarded a $4,311.35 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). The order, issued on July 23, 2025, with an ultimate completion date of July 24, 2025, carries no set-aside designation. Xtandi is a prescription oncology medication used in the treatment of prostate cancer, reflecting DMS Pharmaceutical...
- The Defense Logistics Agency awarded a $12,650.53 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 60 tablets of Xtandi 80 mg. The delivery order, issued on July 25, 2025, with an ultimate completion date of July 28, 2025, carries no set-aside designation. This award is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA under the SPE2DB program, a...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract valued at $8,339.18 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of Xtandi 80 mg tablets. This delivery order is part of a larger single-award indefinite delivery contract (IDC) between the DLA and DMS Pharmaceutical Group, valued up to $499,999,999, that runs through December 31, 2025. The IDC...
- The Defense Logistics Agency awarded a delivery order valued at $4,169.59 to DMS Pharmaceutical Group Inc. for the supply of Xtandi 80 mg tablets (60-count units). The contract, which became effective on July 23, 2025, with an ultimate completion date of July 24, 2025, is structured as a firm fixed-price delivery order with no set-aside designation. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform the work at its...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order on July 30, 2025, for 120 tablets of Xtandi 40 mg with a ceiling value of $8,339.18. This firm fixed-price delivery order, which has an ultimate completion date of July 31, 2025, was issued without a set-aside designation and is funded through the Defense Logistics Agency's Medical Supply Chain. The award represents a single delivery order under DMS...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $8,339.18 by the Defense Logistics Agency on July 28, 2025, for the supply of Xtandi 80 mg tablets (60-count packages). This firm fixed-price delivery order, with an ultimate completion date of July 29, 2025, represents a specific product requisition under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA. The...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract valued at $8,339.18 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the supply of the drug Xtandi 80 mg tablets and has an ultimate completion date of August 27, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) valued at up to $499,999,999 that DMS Pharmaceutical Group holds with...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $4,169.59 to DMS Pharmaceutical Group Inc. for 60 tablets of Xtandi 80 mg, an oncology medication used to treat prostate cancer. The award, issued on July 25, 2025, with an ultimate completion date of July 28, 2025, carries no set-aside designation. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected to fulfill this order under its...
- SPE2DB20D9354Indefinite Delivery Contract
- SPE2DB20D9354-SPE2DB25FX7W5Delivery Order
The Defense Logistics Agency awarded a $8,339.18 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. on August 4, 2025, for the supply of Xtandi 80 mg tablets (60-unit quantity). The contract, which carries no set-aside designation, is scheduled for completion by August 5, 2025, and will be performed at the vendor's facility in Park Ridge, Illinois. Xtandi is a prescription oncology medication used in the treatment of prostate cancer, reflecting DLA's ongoing procurement of specialized pharmaceutical products to support Department of Defense healthcare operations. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, fulfills this delivery order under its substantial single-award Indefinite Delivery Contract with the Defense Logistics Agency valued at $499,999,999 and valid through November 2026. The IDC, established under the SPE2DB program, authorizes DLA to issue firm fixed-price delivery orders across a comprehensive pharmaceutical portfolio including branded and generic prescription drugs, biologics, and medical consumables. This award demonstrates DMS Pharmaceutical Group's established role as a critical supplier within the federal pharmaceutical supply chain, consistently delivering specialized medications and medical products to military health facilities nationwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.3k | 8/4/25 |